Tech Company Financing Transactions

Euthymics Bioscience Funding Round

Euthymics Bioscience, based in Cambridge, scored $24 million from Novartis Venture Fund, GBS Venture Partners and Hambrecht & Quist Capital Management.

Transaction Overview

Company Name
Euthymics Bioscience
Announced On
7/22/2010
Transaction Type
Venture Equity
Amount
$24,000,000
Round
Series A
Investors

Novartis Venture Fund (Lead Investor) (Campbell Murray)

GBS Venture Partners (Andrew Baker)

Hambrecht & Quist Capital Management (Frank Gentile)

Venture Investors (Paul Weiss)

Proceeds Purpose
The initial Series A proceeds were used to complete the acquisition of DOV Pharmaceutical, Inc. and allow for the continued development of DOV's unique antidepressant, EB-1010 (formerly known as DOV 21,947), for patients who do not respond adequately to selective serotonin reuptake inhibitors, or SSRIs.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Bdwy. 14th Floor
Cambridge, MA 02142
USA
Phone
(617) 682-3679
Website
www.euthymics.com
Email Address
[email protected]
Overview
Euthymics Bioscience, a neuroscience-focused biopharmaceutical company, develops medicines for central nervous system disorders.
Profile
Euthymics Bioscience LinkedIn Company Profile
Social Media
Euthymics Bioscience Company Twitter Account
Company News
Euthymics Bioscience News
Facebook
Euthymics Bioscience on Facebook
YouTube
Euthymics Bioscience on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Anthony McKinney
  Anthony McKinney LinkedIn Profile  Anthony McKinney Twitter Account  Anthony McKinney News  Anthony McKinney on Facebook
Chief Marketing Officer
Katherine Laessig
  Katherine Laessig LinkedIn Profile  Katherine Laessig Twitter Account  Katherine Laessig News  Katherine Laessig on Facebook

 

 

Browse more venture capital transactions:

Prev: 7/22/2010: Chiasma venture capital transaction
Next: 7/22/2010: Apixio venture capital transaction

 

Share this article

 

About Our Venture Capital Transactions Database

Our team works diligently to document funding rounds that are announced publicly. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.